StockData
Perspective Therapeutics, Inc. logo

Perspective Therapeutics, Inc. (CATX) stock

CATXNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/30
$0.75−0.03 (-3.85%)

Close on Nov 20, 2026Market cap $86.05MP/E –Yield –

Perspective Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Perspective Therapeutics's ebitda for the twelve months ending Jun 30, 2026 was -$121.18M. For fiscal 2025 it was -$110.31M. The highest annual figure on record is -$2.07M in fiscal 2011.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$110.31M–
FY2024Dec 31, 2024-$88.58M–
FY2017Jun 30, 2017-$6.24M–
FY2016Jun 30, 2016-$4.61M–
FY2015Jun 30, 2015-$3.76M–
FY2014Jun 30, 2014-$3.90M–
FY2013Jun 30, 2013-$3.33M–
FY2012Jun 30, 2012-$2.75M–
FY2011Jun 30, 2011-$2.07M–

Quarterly ebitda

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q2 FY2026CQ2 2026Jun 30, 2026-$28.12M–
Q1 FY2026CQ1 2026Mar 31, 2026-$27.16M–
Q4 FY2025CQ4 2025Dec 31, 2025-$38.82M–
Q3 FY2025CQ3 2025Sep 30, 2025-$27.09M–
Q2 FY2025CQ2 2025Jun 30, 2025-$23.31M–
Q1 FY2025CQ1 2025Mar 31, 2025-$21.10M–
Q4 FY2024CQ4 2024Dec 31, 2024-$44.28M–
Q3 FY2024CQ3 2024Sep 30, 2024-$17.97M–
Q2 FY2024CQ2 2024Jun 30, 2024-$13.69M–
Q1 FY2024CQ1 2024Mar 31, 2024-$12.65M–
Q4 FY2022CQ2 2022Jun 30, 2022-$2.03M–
Q3 FY2022CQ1 2022Mar 31, 2022-$1.30M–
Q4 FY2017CQ2 2017Jun 30, 2017-$1.85M–
Q3 FY2017CQ1 2017Mar 31, 2017-$1.37M–
Q2 FY2017CQ4 2016Dec 31, 2016-$1.46M–
Q1 FY2017CQ3 2016Sep 30, 2016-$1.56M–
Q4 FY2016CQ2 2016Jun 30, 2016-$1.20M–
Q3 FY2016CQ1 2016Mar 31, 2016-$1.19M–
Q2 FY2016CQ4 2015Dec 31, 2015-$1.27M–
Q1 FY2016CQ3 2015Sep 30, 2015-$954.00K–
Q4 FY2015CQ2 2015Jun 30, 2015-$967.79K–
Q3 FY2015CQ1 2015Mar 31, 2015-$916.94K–

More Perspective Therapeutics figures

See a number that looks wrong?